Anti-Inflammatory Therapeutics Market Report 2026

The anti-inflammatory therapeutics market size has grown steadily in recent years. It will grow from $117.28 billion in 2025 to $122.27 billion in 2026 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to rising prevalence of arthritis, increasing cases of inflammatory bowel diseases, growth in hospital pharmacy networks, adoption of corticosteroids, demand for pain management drugs.

The anti-inflammatory therapeutics market size is expected to see strong growth in the next few years. It will grow to $152.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to development of targeted biologics, integration of AI in drug discovery, expansion of online pharmacies, increasing geriatric population, rising focus on personalized medicine. Major trends in the forecast period include personalized anti-inflammatory therapies, increased use of biologic drugs, minimally invasive drug delivery systems, growth in chronic pain management, expansion of online pharmacy distribution.

The rising prevalence of inflammatory bowel disease is expected to drive the growth of the anti-inflammatory therapeutics market in the coming years. Inflammatory bowel disease (IBD) is a chronic condition that causes inflammation in the gastrointestinal tract. Anti-inflammatory therapeutics are essential in managing Crohn’s disease by reducing inflammation, alleviating symptoms, and lowering the need for surgical interventions. For instance, in June 2023, Crohn’s and Colitis Canada, a Canada-based non-profit organization, reported that the number of individuals living with IBD in Canada is projected to reach 470,000 by 2035, up from an estimated 322,600 in 2023. Therefore, the increasing prevalence of inflammatory bowel disease is supporting growth in the anti-inflammatory therapeutics market.

Major companies in the anti-inflammatory therapeutics market are focusing on developing innovative biologic therapies to enhance treatment outcomes for patients with chronic inflammatory conditions. These advanced therapies are designed to provide targeted immune modulation, improved efficacy, and better tolerability compared to traditional treatments such as corticosteroids. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, and Sanofi, a France-based pharmaceutical and healthcare company, launched Kevzara (sarilumab), the first and only anti-inflammatory biologic approved for adult patients with polymyalgia rheumatica (PMR) who do not respond adequately to corticosteroids or cannot tolerate corticosteroid tapering. This novel IL-6 receptor inhibitor offers a more effective, steroid-sparing treatment option, addressing a significant unmet need in PMR management and strengthening the companies’ positions in the anti-inflammatory therapeutics market.

In June 2023, Merck & Co., Inc., a US-based biopharmaceutical company, completed the acquisition of Prometheus Biosciences, Inc. for an undisclosed amount. Through this acquisition, Merck aims to enhance its immunology portfolio by integrating Prometheus’ precision medicine capabilities and its lead candidate PRA023, a targeted therapy in development for immune-mediated diseases such as ulcerative colitis and Crohn’s disease. Prometheus Biosciences, Inc. is a US-based biotechnology company dedicated to developing anti-inflammatory therapeutics.

Major companies operating in the anti-inflammatory therapeutics market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Co. Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.

North America was the largest region in the anti-inflammatory therapeutics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-inflammatory therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the anti-inflammatory therapeutics market by increasing the cost of imported active pharmaceutical ingredients (APIs) and advanced biologic drugs, creating pressure on manufacturers and suppliers. This has most significantly affected the corticosteroids and biologics segments, particularly in regions like North America and Europe that rely on imports from Asia-Pacific manufacturing hubs. While tariffs have raised production costs, they have also incentivized local production and encouraged innovation in cost-effective drug formulations, ultimately supporting regional manufacturing growth.

The anti-inflammatory therapeutics market research report is one of a series of new reports that provides anti-inflammatory therapeutics market statistics, including anti-inflammatory therapeutics industry global market size, regional shares, competitors with a anti-inflammatory therapeutics market share, detailed anti-inflammatory therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the anti-inflammatory therapeutics industry. This anti-inflammatory therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-inflammatory therapeutics are prescription medications used to relieve pain, reduce inflammation, and lower elevated body temperature. They function as host response modifiers and are important in managing acute and chronic headaches, painful episodes, sprains, and strains.

The primary drug classes for anti-inflammatory therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and anti-inflammatory biologics. Nonsteroidal anti-inflammatory drugs are non-opioid analgesics commonly used to alleviate mild pain symptoms in the body. They are indicated for conditions such as arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel diseases, and others, and are distributed through channels including retail pharmacies, hospital pharmacies, and online platforms.

The anti-inflammatory therapeutics market consists of sales of Ibuprofen, naproxen, and diclofenac. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.